Rifaximin for Pertuzumab-Related GI Toxicities

Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy. Rifaximin, a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Soyano, Aixa E., Reynolds, Gina, Moreno-Aspitia, Alvaro, Chumsri, Saranya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550690/
https://www.ncbi.nlm.nih.gov/pubmed/28848707
http://dx.doi.org/10.3389/fonc.2017.00168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550690/
https://www.ncbi.nlm.nih.gov/pubmed/28848707
http://dx.doi.org/10.3389/fonc.2017.00168

Ejemplares similares